Paper Details

  1. Home
  2. Paper Details

Second-line treatment for advanced non-small cell lung cancer: a systematic review.

Author: AstoulPhilippe, BarlésiFabrice, JacotWilliam, PujolJean-Louis

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Overview

Second-line chemotherapy offers a small but significant survival improvement for patients with advanced non-small cell lung cancer (NSCLC) who have resisted or relapsed after first-line chemotherapy. Docetaxel 75 mg/m(2) every 3 weeks is the current standard, and pemetrexed has emerged as a less toxic alternative.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Among advanced non-small cell lung cancer (NSCLC) patients, most will resist or relapse after first-line chemotherapy. As a result, second-line therapy has been a major focus for clinical research. MATERIALS AND METHODS: A systematic review was carried out from 1996 to February 2005. R...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.lungcan.2005.08.017

データ提供：米国国立医学図書館（NLM）

Navigating the Desert of Advanced Lung Cancer Treatment

Non-small cell lung cancer (NSCLC) is a serious and challenging disease. This article explores the options for second-line treatment for patients with advanced NSCLC who have not responded well to initial chemotherapy. It’s like venturing into a new territory in the desert, searching for a different path towards recovery.

The Importance of Second-Line Therapy

The article emphasizes the value of second-line chemotherapy for pre-treated NSCLC patients, offering a potential survival advantage. It’s like finding a new source of water in a parched desert, providing a lifeline for those facing difficult circumstances.

Emerging Treatment Strategies

The article discusses the use of docetaxel and pemetrexed as second-line treatments, highlighting their potential efficacy and safety. It also mentions the ongoing research into targeted therapies, offering hope for even more effective treatments in the future. It’s like discovering new tools and techniques for navigating the desert, making it easier to overcome the challenges and find a way forward.

Dr.Camel's Conclusion

This article provides a comprehensive overview of second-line treatment options for advanced NSCLC. It’s a reminder that the search for better treatments for this disease is an ongoing journey. Just as a camel adapts to the harsh conditions of the desert, so too must we continue to explore new solutions and advance our knowledge in the fight against lung cancer.

Date :
  1. Date Completed 2006-06-08
  2. Date Revised 2018-12-03
Further Info :

Pubmed ID

16360238

DOI: Digital Object Identifier

10.1016/j.lungcan.2005.08.017

Related Literature

Article Analysis
・Effective treatment of lung cancer
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.